FREMONT, Calif. — WaferGen Bio-systems, Inc. (Nasdaq:WGBS) today announced the first commercial sale of WaferGen’s ICELL8™ Single-Cell System to a major global pharmaceutical company. The system will enable greater single-cell throughput, and provide key insights to be used in important cancer-related research initiatives.

“The first commercial sale of our ICELL8 Single-Cell System is a significant milestone for WaferGen,” said Rolland Carlson, President and Chief Executive Officer of WaferGen. “Based on the extensive results generated from our early access partners and in-house WaferGen research and development initiatives that have demonstrated the system’s performance and utility, we think the ICELL8 has significant commercial potential. The ability to select specific cells based on cell imaging, combined with user friendly and cost-efficient processing methods, makes the ICELL8 very attractive to our targeted corporate and academic customers.”

The ICELL8 Single-Cell System is a revolutionary platform which can isolate thousands of single cells and process specific cells of interest for downstream analysis using Next Generation Sequencing. The system also includes an imaging station and CellSelect™ software for imaging each nanowell and automatic selection of single cells for downstream processing. Recently, WaferGen presented proof of concept results at the Single Cell Analyses Conference at the Cold Spring Harbor Laboratory demonstrating the flexibility of the ICELL8 System to isolate and specifically detect cells stained with fluorescently-labeled antibodies specific for Her2p. ICELL8’s throughput and ability to choose specific cells is enabling a wide range of applications, including stem cell, neuroscience, immunology, and cancer research.

About WaferGen

WaferGen Bio-systems, Inc. is a biotechnology company that offers innovative genomic technology solutions for single cell analysis and clinical research. The ICELL8™ Single Cell System is a cutting edge platform which can isolate thousands of single cells and processes specific cells for analysis, including Next Generation Sequencing (NGS). The system has demonstrated unbiased isolation of up to 1,800 single cells ranging from 5-100 µm in size on a single chip, including single cells from solid tumors, brain cells, pulmonary airway cells, and multiple cell lines. The SmartChip™ platform can be used for profiling and validating molecular biomarkers, and can perform massively parallel singleplex PCR for one-step target enrichment and library preparation for clinical NGS. The Apollo 324™ system can be used to process DNA and RNA from clinical samples to NGS-ready libraries. These technologies offer a powerful set of tools for biological analysis at the molecular and single cell level in the life sciences, pharmaceutical, and clinical laboratory industries.